Gene-expression profiles predict survival of patients with lung adenocarcinoma

Nature Medicine

Volumn 8, Issue 8, 2002, Pages 816-824

  Beer, David G ^a   Kardia, Sharon L R ^a   Huang, Chiang Ching ^a   Giordano, Thomas J ^a   Levin, Albert M ^a   Misek, David E ^a   Lin, Lin ^a   Chen, Guoan ^a   Gharib, Tarek G ^a   Thomas, Dafydd G ^a   Lizyness, Michelle L ^a   Kuick, Rork ^a   Hayasaka, Satoru ^a   Taylor, Jeremy M G ^a   Iannettoni, Mark D ^a   Orringer, Mark B ^a   Hanash, Samir ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DNA MICROARRAY; GENE AMPLIFICATION; GENE EXPRESSION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPHOCYTIC INFILTRATION; ONCOGENE K RAS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSEUDOGENE; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; VALIDATION PROCESS;

ADENOCARCINOMA; COHORT STUDIES; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE;

EID: 18544365698     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm733     Document Type: Article

References (45)

1. Ten-year survey of lung cancer treatments and survival in hospitals in the United States
2. Survival of patients surgically treated for stage I lung cancer
3. Postsurgical stage I bronchogenic carcinoma: Morbid implications of recurrent disease
4. Prognosis and survival in resected carcinoma based on the new international staging system
5. Evolving features of lung adenocarcinoma in Rio de Janeiro, Brazil
6. Lung cancer heterogeneity: A blinded and randomized study of 100 consecutive cases
7. Prognostic factors in patients with resected stage I non-small cell lung cancer: A report from the Lung Cancer Study Group
8. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter
9. Is T factor of the TMN staging system a predominant prognostic factor in pathologic stage I non-small cell lung cancer
10. A prognostic model of recurrence and death in stage I nonsmall cell lung cancer utilizing presentation, histopathology, and oncoprotein expression
11. Mutational activation of the K-ras oncogene: A possible pathogenic factor in adenocarcinoma of the lung
12. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung
13. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer
14. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas
15. Relationship of p53 overexpresson and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer
16. Prognostic markers in resected stage I and II non-small cell lung cancer: An analysis of 260 patients with 5 year follow-up
17. Multiple molecular marker testing (p53, c-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer
18. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma
19. Molecular profiling of human cancer
20. Editorial: Genome-wide views of cancer
21. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
22. Diversity of gene expression in adenocarcinoma of the lung
23. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma
24. Organ-specific molecular classification of lung, colon and ovarian adenocarcinomas using gene expression profiles
25. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene
26. IGFBP-3 mediates TGF β 1 proliferative response in colon cancer cells
27. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women
28. Up-regulation of heat shock protein 70 in adenocarcinoma of the lung in smokers
29. Heat shock protein hsp70 in patients with auxillary lymph nodepositive breast cancer: Prognostic implications
30. Total lactate dehydrogenase and its isoenzymes in serum of patients with non-small cell lung cancer
31. Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer
32. Cysteine proteinases and their inhibitors in extracellular fluids; Markers for diagnosis and prognosis in cancer
33. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
34. Gene-expression profiles in hereditary breast cancer
35. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer
36. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma
37. A direct interaction between JNK1 and Crkll is critical for Rac1-induced JNK activation
38. The Ras-mitogen-activated protein kinase pathway is critical for the activation of matrix metalloproteinase secretion and the invasiveness in v-crk-transformed 3Y1
39. The hallmarks of cancer
40. Expression of the glucocorticoid receptor and K-ras genes in urethan-induced mouse lung tumors and transformed cell lines
41. A minimal critical region of the 8p22-23 amplicon in esophageal adenocarcinomas defined using STS-amplification mapping and quantitative PCR includes the GATA-4 gene
42. Tissue microarrays for high throughput molecular profiling of tumor specimens
43. Applied Multivariate Statistical
44. Asymptomics for and against cross-validation
45. Regression models and life tables